SCHEDULE: Lytton Group Discloses 9.99% Stake in Aytu BioPharma
Beneficial Ownership Report
Laurence W. Lytton and the Lytton-Kambara Foundation reported a combined beneficial ownership of 9.99% in AYTU BIOPHARMA, INC common stock.
Summary
- Laurence W. Lytton and the Lytton-Kambara Foundation jointly reported beneficial ownership of 1,086,522 shares of AYTU BIOPHARMA, INC common stock.
- This ownership represents 9.99% of the company's outstanding common stock.
- The reported stake comprises 122,063 shares of common stock and warrants to purchase 1,831,666 shares of common stock, subject to a 9.99% beneficial ownership limitation.
- The percentage of class is calculated based on 9,911,913 shares of Common Stock outstanding as of September 15, 2025, as disclosed in the Issuer's Form 10-K for the fiscal year ended June 30, 2025.
- The reporting persons hold sole voting and dispositive power over 1,054,752 shares and shared voting and dispositive power over 31,800 shares.
- The filing includes a certification that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of beneficial ownership and does not contain performance or operational updates.
Industry Context
This filing is a routine disclosure of a significant ownership stake by an individual and a foundation, which is a standard regulatory requirement across all industries for publicly traded companies. It does not provide specific industry-related insights for AYTU BIOPHARMA.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Certification | Reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11. | 2025-11-14 | This certification indicates a passive investment stance by the reporting persons, suggesting they do not intend to engage in activist campaigns to take control of the company, beyond potentially nominating directors. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional and individual ownership stake, which can be a factor in assessing the stability and composition of the company's shareholder base.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | End of fiscal year for which AYTU BIOPHARMA, INC filed its Form 10-K. |
| 2025-09-15 | Date as of which 9,911,913 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-K. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-14 | Date of signing and filing of the Schedule 13G statement. |
Keywords
AYTU BIOPHARMA, AYTU, Common Stock, Schedule 13G, Beneficial Ownership, Laurence W. Lytton, Lytton-Kambara Foundation, Institutional Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.